Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.61 |
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540551 | 1.00 | TLR2 (0.61) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL14445569 | 1.00 | TLR2 (0.61) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29540527 | 1.00 | TLR2 (0.61) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL12917713 | 0.90 | TLR2 (0.67) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29907908 | 0.88 | CASP3 (0.56) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29907963 | 0.88 | CASP3 (0.56) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL11885249 | 0.88 | TLR2 (0.58) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL16343063 | 0.88 | CASP3 (0.56) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL16218324 | 0.88 | CASP3 (0.56) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL12787770 | 0.88 | TLR2 (0.58) | TLR2MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-30 | — | — | US | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| WO-2017072062-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-04 | — | — | WO | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013100132-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | 中外製薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | TLR2 3462/4885MDM4 3559/4885TP53 2654/4885 |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | TLR2 200/4885MDM4 3771/4885TP53 3724/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | TLR2 200/4885MDM4 3771/4885TP53 3724/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | TLR2 3462/4885MDM4 3559/4885TP53 2654/4885 |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | TLR2 3462/4885MDM4 3559/4885TP53 2654/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | TLR2 3462/4885MDM4 3559/4885TP53 2654/4885 |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | VIP, DNPEP, HM13 | TLR2 3912/4885MDM4 3098/4885TP53 3050/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | TLR2 3462/4885MDM4 3559/4885TP53 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.